In the last three months, 18 analysts have published ratings on Veeva Sys VEEV, offering a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 5 | 8 | 4 | 1 | 0 |
Last 30D | 0 | 1 | 0 | 0 | 0 |
1M Ago | 2 | 3 | 1 | 0 | 0 |
2M Ago | 2 | 2 | 3 | 1 | 0 |
3M Ago | 1 | 2 | 0 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $209.44, with a high estimate of $265.00 and a low estimate of $160.00. A decline of 3.56% from the prior average price target is evident in the current average.
Investigating Analyst Ratings: An Elaborate Study
A clear picture of Veeva Sys's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
Brent Bracelin | Piper Sandler | Raises | Overweight | $220.00 | $200.00 |
Scott Schoenhaus | Keybanc | Lowers | Overweight | $210.00 | $230.00 |
David Grossman | Stifel | Maintains | Buy | $205.00 | - |
David Hynes | Canaccord Genuity | Lowers | Hold | $185.00 | $210.00 |
Saket Kalia | Barclays | Lowers | Overweight | $213.00 | $220.00 |
Ryan MacDonald | Needham | Maintains | Buy | $220.00 | - |
Brent Bracelin | Piper Sandler | Maintains | Overweight | $200.00 | - |
Anne Samuel | JP Morgan | Lowers | Neutral | $183.00 | $188.00 |
Jailendra Singh | Truist Securities | Lowers | Hold | $187.00 | $227.00 |
Jailendra Singh | Truist Securities | Maintains | Hold | $227.00 | - |
Craig Hettenbach | Morgan Stanley | Lowers | Underweight | $160.00 | $181.00 |
Gabriela Borges | Goldman Sachs | Lowers | Buy | $216.00 | $244.00 |
Brian Peterson | Raymond James | Lowers | Outperform | $200.00 | $240.00 |
Ryan MacDonald | Needham | Maintains | Buy | $220.00 | - |
Brent Bracelin | Piper Sandler | Lowers | Overweight | $200.00 | $235.00 |
Stan Berenshteyn | Wells Fargo | Raises | Overweight | $229.00 | $211.00 |
David Windley | Jefferies | Announces | Buy | $265.00 | - |
Scott Schoenhaus | Keybanc | Raises | Overweight | $230.00 | $220.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Veeva Sys. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Veeva Sys compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of Veeva Sys's stock. This comparison reveals trends in analysts' expectations over time.
For valuable insights into Veeva Sys's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on Veeva Sys analyst ratings.
Delving into Veeva Sys's Background
Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company's best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company.
Key Indicators: Veeva Sys's Financial Health
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Positive Revenue Trend: Examining Veeva Sys's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 11.61% as of 31 October, 2023, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 21.92%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Veeva Sys's ROE excels beyond industry benchmarks, reaching 3.17%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.59%, the company showcases effective utilization of assets.
Debt Management: Veeva Sys's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.01.
The Basics of Analyst Ratings
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.